Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04284293 · ClinicalTrials.gov registry record · Phase 1
CNS10-NPC for the Treatment of RP
A Phase 1 study of Retinitis Pigmentosa, sponsored by Cedars-Sinai Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04284293: Active Phase 1 study of Retinitis Pigmentosa, sponsored by Cedars-Sinai Medical Center.
NCT04284293 is a Phase 1 study of Retinitis Pigmentosa that is active but no longer recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 16 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04284293, a Phase 1 study of Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Cedars-Sinai Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The cells are called "CNS10-NPC." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if CNS10-NPC cells are safe to transplant into the subretinal space of people.
Conditions Studied
Interventions
- BIOLOGICAL CNS10-NPC implantation
Study Locations (1)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What the registry record for NCT04284293 still lists
NCT04284293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which CNS10-NPC implantation is the first listed.
NCT04284293 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04284293 about?
NCT04284293 is a clinical study titled "CNS10-NPC for the Treatment of RP". The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have b...
What is the current status of trial NCT04284293?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-07-22. Estimated completion is 2026-07.
What conditions does trial NCT04284293 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT04284293?
The interventions under investigation include: CNS10-NPC implantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT04284293?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04284293 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04284293's enrollment target sits among peer trials
16 29th of 37 higher than 9 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI